Syöpäklinikka TO6

Julkaisut 2013
Publications 2013

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Autio A et al. Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation.
2 Avoranta ST et al. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.
3 Avoranta T. The Prognostic and Predictive Value of Selected Biomarkers in Colorectal Cancer.
4 Benberin V et al. Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers.
5 Coleman R et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
6 Elme A et al. Obesity and physical inactivity are related to impaired physical health of breast cancer survivors.
7 Elzagheid A et al. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer.
8 Elzagheid A et al. Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma.
9 Ermiah E. Libyan breast cancer: Health services and biology. Diagnosis delay and prognostic value of DNAploidy, S-phase fraction, and Ki-67 and Bcl-2 immunohistochemistry.
10 Ermiah E et al. Prognostic value of bcl-2 expression among women with breast cancer in Libya.
11 Heiskanen T et al. Kipu palliatiivisessa hoidossa.
12 Holte H et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
13 Jaakkola PM, Rantanen K. The regulation, localization, and functions of oxygen-sensing prolyl hydroxylase PHD3.
14 Joensuu H et al. Syöpätaudit. 5., uudistettu painos.
15 Kalhori V et al. Sphingosine-1-phosphate as a regulator of hypoxia-induced factor-1a in thyroid follicular carcinoma cells.
16 Kauhanen S et al. Positroniemissiotomografian ja magneettikuvauksen yhdistelmällä tarkkuutta onkologiseen kuvantamiseen?
17 Kellokumpu-Lehtinen PL et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
18 Kero K et al. Reply to Kathleen D'Hauwers, Gunter De Win and Wiebren Tjalma's letter to the editor re: Katja Kero, Jaana Rautava, Kari Syrjänen, Seija Grenman, Stina Syrjänen. Oral mucosa as a reservoir of human papillomavirus: . point prevalence, genotype distribution, and incident infections among males in a 7-year prospective study. Eur Urol 2012;62:1063-70.
19 Kersten C et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer.
20 Knuuti J et al. Is cardiac magnetic resonance imaging causing DNA damage?
21 Korkeila E. Feed Back.
22 Koskela H et al. Disease outcome of patients with pancreatic cancer in a cohort treated outside clinicla trials .
23 Koskimies P et al. Oral bioavailability of ospemifene improves with food intake.
24 Kähkönen E et al. In Vivo imaging of prostate cancer using (68Ga)-labeled bombesin analog BAY86-7548.
25 Lindholm P, Kivioja A. Luusarkooma.
26 Louvanto K et al. Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: A six-year follow-up study.
27 Monsonego J et al. Prevalence of genotype-specific HPV infection among women in France: Implications for screening and vaccination (in French).
28 Närvä E et al. Continuous hypoxic culturing of human embryonic stem cells enhances SSEA-3 and MYC levels.
29 Rantanen K et al. p62/SQSTM1 regulates cellular oxygen sensing by attenuating PHD3 activity through aggregate sequestration and enhanced degradation.
30 Ristamäki R. Endokriiniset syövät.
31 Roberts PJ et al. Mahasyöpä.
32 Roberts PJ et al. Maksan ja sappiteiden syöpä.
33 Roivainen A et al. Plasma pharmacokinetics, whole-body distribution metabolism, and radiation dosimetry of 68ga bombesin antagonist BAY 86-7548 in healthy men.
34 Salminen E. Ympäristöherkkyys- taistelu tuulimyllyjä vastaan?
35 Salminen EK et al. Opioids in pain management of mesothelioma and lung cancer patients.
36 Salminen P, Ristamäki R. Leikkauskelpoisen mahasyövän perioperatiivinen solunsalpaajahoito - näyttöön perustuvasta hoidosta kliiniseksi käytännöksi.
37 Salomaa S et al. State of the art in research into the risk of low dose radiation exposure-findings of the fourth MELODI workshop.
38 Suominen E. et al. Ihosyövän yleisyys ja vaaratekijät.
39 Syrjänen K. Geographic origin is a significant determinant of human papillomavirus prevalence in oesophageal squamous cell carcinoma: Systematic review and meta-analysis.
40 Syrjänen K. Suomalainen FIT-testi: Entistä tehokkaampaa suolistosyövän seulontaa.
41 Syrjänen K. Yksinkertainen testi paljastaa onko mahalaukku terve.
42 Syrjänen K. Keynotes from the new editor-in-chief.
43 Syrjänen K, Syrjänen S. Detection of human papillomavirus in sinonasal carcinoma: systematic review and meta-analysis.
44 Syrjänen K, Syrjänen S. Detection of human papillomavirus in esophageal papillomas: systematic review and meta-analysis.
45 Syrjänen K, Syrjänen S. Detection of human papillomavirus in sinonasal papillomas:systematic review and meta-analysis.
46 Syrjänen K, Syrjänen S. Solitary bronchial squamous cell papilloma - another human papillomavirus (HPV)-associated benign tumor: systematic review and meta-analysis.
47 Syrjänen S et al. Competing-risks regression models in analysis of biomarkers as predictors of high-risk human papillomavirus (HPV) infection outcomes and incident CIN in the LAMS cohort.
48 Ylönen O et al. Kivessyövän hoito ja seuranta räätälöidään riskiluokituksen mukaan .

Julkaisutietokanta 12.9.2014 Publications Data Base 12.9.2014